Twist Bioscience Corp (TWST) - Total Liabilities
Based on the latest financial reports, Twist Bioscience Corp (TWST) has total liabilities worth $221.12 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore TWST shareholders equity momentum to track the company's year-over-year net asset growth rate.
Twist Bioscience Corp - Total Liabilities Trend (2016–2025)
This chart illustrates how Twist Bioscience Corp's total liabilities have evolved over time, based on quarterly financial data.
Twist Bioscience Corp Competitors by Total Liabilities
The table below lists competitors of Twist Bioscience Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PROTECTOR FORSIKR.(ADS)/2
F:PR40
|
Germany | €21.00 Billion |
|
Skeena Resources Ltd
TO:SKE
|
Canada | CA$611.07 Million |
|
nLIGHT Inc
NASDAQ:LASR
|
USA | $91.36 Million |
|
KPJ Healthcare Bhd
KLSE:5878
|
Malaysia | RM5.04 Billion |
|
Uni-President China Holdings Ltd
F:58U
|
Germany | €10.89 Billion |
|
Jointown Pharmaceutical Group Co Ltd
SHG:600998
|
China | CN¥77.21 Billion |
|
Advance Auto Parts Inc
NYSE:AAP
|
USA | $9.63 Billion |
|
CIE Automotive S.A.
MC:CIE
|
Spain | €3.78 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Twist Bioscience Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TWST stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Twist Bioscience Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Twist Bioscience Corp (2016–2025)
The table below shows the annual total liabilities of Twist Bioscience Corp from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $168.90 Million | +19.25% |
| 2024-09-30 | $141.63 Million | -7.41% |
| 2023-09-30 | $152.97 Million | -11.06% |
| 2022-09-30 | $171.99 Million | +41.82% |
| 2021-09-30 | $121.28 Million | +93.67% |
| 2020-09-30 | $62.62 Million | +79.37% |
| 2019-09-30 | $34.91 Million | -88.99% |
| 2018-09-30 | $317.21 Million | +44.84% |
| 2017-09-30 | $219.01 Million | +43.08% |
| 2016-09-30 | $153.07 Million | -- |
About Twist Bioscience Corp
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo … Read more